that admission PDW and MPV values are independent correlates of no-reflow and in-hospital major adverse cardiovascular events (MACEs) among patients with STEMI undergoing primary PCI. In addition, in-stent thrombosis, nonfatal MI, in-hospital mortality, and MACEs were significantly more frequent among patients with no-reflow. Interestingly, the use of glycoprotein IIb/IIIa inhibitor was significantly greater among patients with no-reflow in their study. Jagroop and Mikhailidis stated that fibrinogen had no effect on platelet shape change (PSC), an early phase of platelet activation, and adenosine diphosphate-and serotonin-induced PSC was not inhibited by the glycoprotein IIb/IIIa inhibitor tirofiban. 16 Previous studies showed that exposure of a subthreshold level of platelet inhibition can paradoxically induce platelet activation and release the chemokines and proinflammatory mediators. 13, 14 The underlying mechanism of coronary thrombosis in patients with acute coronary syndrome is plaque rupture that allows contact of platelets with the highly thrombogenic necrotic core. 17 However, total stent length, incomplete stent expansion, and existence of coronary dissection after stent implantation are the major reasons for early stent thrombosis. 18 In addition to angiographic and procedural properties, many factors may contribute to early stent thrombosis such as clinical and genetic variability and medical treatment regimes. Consequently, despite the different underlying causes, we think that increased MPV and PDW are markers of acute stent thrombosis in patients undergoing primary or elective PCI, despite the use of glycoprotein IIb/IIIa inhibitors. Further clinical trials are needed to clarify this issue.
